• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genetic Technologies Ltd

    10/31/24 8:11:01 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GENE alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    FORM 6-K

    U.S. SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of October , 2024

     

    Commission File Number 0-51504

     

    GENETIC TECHNOLOGIES LIMITED

    (Exact Name as Specified in its Charter)

     

    N/A

    (Translation of Registrant’s Name)

     

    60-66 Hanover Street

    Fitzroy

    Victoria 3065 Australia

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File Nos. 333-276168), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     

     

     
     

     

    Exhibit Index

     

    Exhibit No.   Description
         
    Exhibit 99.1   Appendix 4C & Quarterly Business Update – September 2024

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: October 31, 2024

     

    GENETIC TECHNOLOGIES LIMITED  
       
    By: /s/ Mark Ziirsen  
    Name: Mark Ziirsen  
    Title: Company Secretary  

     

     

    Get the next $GENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GENE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GENE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Join Genetic Technology's Exclusive Live Investor Webinar and Q&A Session on October 2

      MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies' senior leadership who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, along with progress on its recent move to a capital light model. Genetic Technologies' EasyDNA platform has over $7m in annual recur

      9/23/24 8:30:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genetic Technologies Ltd (Amendment)

      SC 13G/A - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/14/24 2:14:47 PM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genetic Technologies Ltd

      SC 13G - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/13/23 10:20:55 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Financials

    Live finance-specific insights

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corp

      4/12/24 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a

      12/29/23 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GENE
    Leadership Updates

    Live Leadership Updates

    See more
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

      MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.  More r

      7/16/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • GTG to launch U.S. Customer Digital Media Sales Campaign

      MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be

      2/28/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    SEC Filings

    See more
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/12/24 8:00:15 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/2/24 8:00:04 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      11/20/24 8:00:07 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care